FTY720 + Placebo
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Progressive Multiple Sclerosis
Conditions
Primary Progressive Multiple Sclerosis
Trial Timeline
Jul 28, 2008 → Jun 22, 2015
NCT ID
NCT00731692About FTY720 + Placebo
FTY720 + Placebo is a phase 3 stage product being developed by Novartis for Primary Progressive Multiple Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00731692. Target conditions include Primary Progressive Multiple Sclerosis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Progressive Multiple Sclerosis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00785083 | Phase 2 | Completed |
| NCT00731692 | Phase 3 | Terminated |
| NCT00537082 | Phase 2 | Completed |
| NCT00333138 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Progressive Multiple Sclerosis